Liverpool to trial new pancreatic cancer therapy
Patients in Liverpool are to trial a new therapy for pancreatic cancer â€“ a disease which sees most sufferers die within a year of diagnosis.
One of the 10 most common cancers in the UK, it is among the most difficult to diagnose and treat and kills around 7,000 people each year. There are very few early symptoms so most patients present late and only around 15% are suitable for surgery.
The Phase III TeloVac trial has been designed by the Pancreatic Cancer Clinical Sub-Group of the UK National Cancer Research Institute and will be run by Cancer Research UKâ€™s Liverpool Cancer Trials Unit.
Funded by Cancer Research UK, the trial will test the vaccine GV1001 alongside two chemotherapyterm drugs gemcitabine and capecitabinetermterm on patients with locally advanced and metastaticterm pancreatic cancer. GV1001 is a new immunotherapeutic drug for pancreatic cancer developed by Danish-based biotech company Pharmexa.
One of the trialâ€™s two principal investigators, Professor John Neoptolemos, based at the University of Liverpool and a consultant surgeon at the Royal Liverpool University Hospital, said: "The National Cancer Research Institute is very committed to this trial and is focusing a great deal of energy on recruiting patients to take part in it. This is because we firmly believe that GV1001 could play a key role in the future treatment of pancreatic cancer."
He added: "Weâ€™re proud to manage this fundamental trial at the Liverpool Cancer Trials Unit and we hope other centres in the UK will participate in order to achieve maximum benefit for patients suffering from locally advanced and metastatic pancreatic cancer."
Chief Investigator Dr Gary Middleton from the Royal Surrey County Hospital, who is working alongside Professor Neoptolemos and Professor David Cunningham from the Royal Marsden Hospital, said: "We believe the future treatment of pancreatic cancer, as well as many other cancers, will include combinations of various chemotherapies together with biological and targeted therapies.
"GV1001 is a particularly attractive vaccine; the antigen that it targets is expressed on virtually all pancreatic cancer cells and the vaccine stimulates the production of all of the cells that are required for an effective immune attack upon these cancers. Adding it to the platform of chemotherapy is an exciting strategy which, if successful, would create a new standard of care in this disease."
Professor John Toy, Medical Director at Cancer Research UK, said: "New treatments are desperately needed for pancreatic cancer as survival rates are so poor. GV1001 is a new generation of agent that harnesses the bodyâ€™s own immune system to fight cancer. We are delighted to be funding a trial of such an innovative treatment."
Patients with non-resectable pancreatic cancer will be randomly distributed into one of three arms of the trial:
- 370 patients will be treated with gemcitabine and capecitabine in a standard treatment
- 370 patients will be treated first with gemcitabine and capecitabine for eight weeks, following which they will be treated with GV1001
- 370 patients will be treated with gemcitabine and capecitabine and with GV1001 at the same time
The research team aims to find whether the patients treated with a combination of GV1001 and chemotherapy live longer than patients who only receive chemotherapy. It is not expected that GV1001 will cure patients, but that treatment will prolong their lives and that a small proportion of the patients may experience significantly longer survival.